Literature DB >> 2007360

Gastroduodenal mucosal prostaglandin generation in patients with Helicobacter pylori before and after treatment with bismuth subsalicylate.

C Avunduk1, M Suliman, D Gang, N Polakowski, G L Eastwood.   

Abstract

To determine whether Helicobacter pylori has an effect on gastroduodenal mucosal prostaglandin generation, mucosal biopsies were obtained from the gastric body, antrum, and duodenal bulb of 30 patients who were undergoing upper gastrointestinal endoscopy for clinical indications. One biopsy from the gastric body and one from the antrum were tested for urease activity (urea broth) and one biopsy from each area including the duodenum was processed for histology. Two other biopsies form each area were incubated and the accumulation of prostaglandin E2 and 6-keto prostaglandin F1 alpha in the incubation medium was measured by radioimmunoassay. Twelve of the 17 H. pylori-positive patients and seven of the 13 H. pylori-negative patients agreed to take bismuth subsalicylate (Pepto-Bismol) two tablets four times a day for four weeks. One week after treatment, these patients again underwent endoscopy and the above studies. This study indicates that: (1) mucosal PGE2 generation may be increased in the duodenum, gastric body, and antrum in H. pylori-positive patients compared to H. pylori-negative patients, and (2) treatment with bismuth subsalicylate for four weeks results in reduction of mucosal PGE2 in the duodenum, gastric body, and antrum of H. pylori-positive patients and fails to eradicate H. pylori or reduce gastric inflammation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2007360     DOI: 10.1007/bf01298870

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  10 in total

1.  Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate.

Authors:  C A McNulty; J C Gearty; B Crump; M Davis; I A Donovan; V Melikian; D M Lister; R Wise
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-13

2.  Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment.

Authors:  E A Rauws; W Langenberg; H J Houthoff; H C Zanen; G N Tytgat
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

Review 3.  Current history of cytoprotection.

Authors:  A Robert
Journal:  Prostaglandins       Date:  1981

4.  Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial.

Authors:  H Humphreys; S Bourke; C Dooley; D McKenna; B Power; C T Keane; E C Sweeney; C O'Moráin
Journal:  Gut       Date:  1988-03       Impact factor: 23.059

5.  Prostaglandins and cannabis--IX. Stimulation of prostaglandin E2 synthesis in human lung fibroblasts by delta 1-tetrahydrocannabinol.

Authors:  S Burstein; S A Hunter; C Sedor; S Shulman
Journal:  Biochem Pharmacol       Date:  1982-07-15       Impact factor: 5.858

Review 6.  Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms.

Authors:  T A Miller
Journal:  Am J Physiol       Date:  1983-11

7.  Campylobacter pylori, duodenal ulcer, and gastric metaplasia: possible role of functional heterotopic tissue in ulcerogenesis.

Authors:  J Carrick; A Lee; S Hazell; M Ralston; G Daskalopoulos
Journal:  Gut       Date:  1989-06       Impact factor: 23.059

8.  Detection of Campylobacter pylori by the biopsy urease test: an assessment in 1445 patients.

Authors:  C A McNulty; J C Dent; J S Uff; M W Gear; S P Wilkinson
Journal:  Gut       Date:  1989-08       Impact factor: 23.059

9.  Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH.

Authors:  A Morris; G Nicholson
Journal:  Am J Gastroenterol       Date:  1987-03       Impact factor: 10.864

10.  Campylobacter pyloridis gastritis II: Distribution of bacteria and associated inflammation in the gastroduodenal environment.

Authors:  S L Hazell; W B Hennessy; T J Borody; J Carrick; M Ralston; L Brady; A Lee
Journal:  Am J Gastroenterol       Date:  1987-04       Impact factor: 10.864

  10 in total
  5 in total

1.  NSAID gastric ulceration: predictive value of gastric pH, mucosal density of polymorphonuclear leukocytes, or levels of IL-8 or nitrite.

Authors:  Akiko Shiotani; Yoshio Yamaoka; Hala M T El-Zimaity; M Ali Saeed; Waqar A Qureshi; David Y Graham
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

2.  Prostaglandin E2 and prostaglandin F2 alpha biosynthesis in human gastric mucosa: effect of chronic alcohol misuse.

Authors:  C Bode; G Maute; J C Bode
Journal:  Gut       Date:  1996-09       Impact factor: 23.059

3.  Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly: a case-control study.

Authors:  A Pilotto; G Leandro; F Di Mario; M Franceschi; L Bozzola; G Valerio
Journal:  Dig Dis Sci       Date:  1997-03       Impact factor: 3.199

4.  The association between cagA+ H. pylori infection and distal gastric cancer: a proposed model.

Authors:  Mohammed S Al-Marhoon; Sheila Nunn; Roger W Soames
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

5.  Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs.

Authors:  N Hudson; M Balsitis; F Filipowicz; C J Hawkey
Journal:  Gut       Date:  1993-06       Impact factor: 23.059

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.